Tandem Diabetes rises as Piper Sandler upgrades rating

Tandem Diabetes Care

17/03/2026 10:39

** Shares of diabetes technology company Tandem Diabetes Care TNDM.O rise ~4.29% to $22.85 premarket

** Piper Sandler upgrades TNDM to "overweight" from "neutral" rating, citing improved pharmacy pricing benefits and growing international direct market opportunities

** Brokerage says there is meaningful upside to revenue estimates over the next three years, which will push stock higher

** Expects the co's new tubeless Mobi product to boost pump shipments in the coming years and help TNDM regain market share.

** Piper Sandler raises PT to $33, a 50.6% upside on stock's last close

** 11 of 24 brokerages rate the stock "buy" or higher, 13 "hold"; their median PT is $27.50 - LSEG data

** As of last close, stock down ~0.3% YTD

 (Reporting by Prakhar Srivastava in Bengaluru)

 ((Prakhar.srivastava2@thomsonreuters.com))